IMMUNOHISTOCHEMISTRY IN ENDOMETRIAL HYPERPLASIA AND ENDOMETRIAL ADENOCARCINOMA
Abstract
Aim: Endometrial hyperplasia is a proliferation of endometrial glands due to the prolonged stimulation with estrogens of the endometrium that occurs in women receiving exogenous estrogens, with anovulatory cycles, or in patients with ovarian tumours with estrogen secretion. Material and methods: The study performed by the authors included 575 patients with endometrial hyperplasia and 163 patients with endometrial adenocarcinoma admitted to the “Cuza-Vodă” Obstetrics and Gynaecology Clinical Hospital of Iasi, between 2005-2007. Results: There were selected, for these immunohistochemistry reactions, 22 cases of simple hyperplasia without atypia, 26 cases of complex hyperplasia without atypia, 23 cases of endometrial adenocarcinoma of endometrioid type, well differentiated, 22 cases of endometrial adenocarcinoma of endometrioid type, moderately differentiated, and 19 cases of non-endometrioid adenocarcinomas represented by nine clear cells and 10 serous endometrial adenocarcinomas. Estrogen receptors have been positive in about 85-90% of the tumour cells of the well-differentiated endometrial adenocarcinomas of endometrioid type (GI). In endometrioid-type endometrial adenocarcinomas moderately differentiated (GII), the estrogen receptors were positive in approximately 70-85% of the tumour cells. Conclusions: Endometrial hyperplasia, especially complex endometrial hyperplasia with atypia, increase the risk for endometrial adenocarcinoma, and their early detection becomes mandatory under cancer prevention. Well-differentiated endometrioid endometrial adenocarcinomas were ER and PR-positive, so that the ER expression correlated with the PR expression. Well-differentiated endometrioid endometrial adenocarcinomas (GI) in the studied group also showed a higher content of ER and PR compared to the endometrial moderately-differentiated endometrioid endometrial adenocarcinomas (GII). In non-endometrioid adenocarcinomas, represented by clear-cell endometrial adenocarcinomas, the ER content was reduced and the PR expression was negative. Serous adenocarcinomas failed to show an immunohistochemically expression for ER and PR.
References
2. Kohler MF, Berchuck A, Davidoff AM et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992; 52: 1622-1627.
3. Enomoto T, Fujita M, Inoue M et al. Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 1991; 51: 5308-5314.
4. Mizuuchi W, Masims S, Kudo R et al. Clinical implications of K-ras mutations in malignant epithelial tumors of the endometrium. Cancer Res 1992; 52: 2777-2781.
5. Matias-Guiu X.Microsatellite instability in endometrial carcinomas. IAP Congress Amsterdam, 2002.
6. Cheung ANY. Tumor suppressor genes and oncogenes in gynaecological tumours. IAP Congress Amsterdam 2002.
7. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G.Expression of cyclooxygenase-2(COX-2), receptors for estrogen(ER), and progesterone (PR), p53, Ki67, and neu protein in endometrial cancer. Gynecol Oncol 2005; 98: 383-389
8. Honkavuori M, Talvensaari-Mattila A, Soini Y, Turpeenniemi-Hujanen T, Santala M.MMP-2 expres-sion associates with CA 125 and clinical course in endometrial carcinoma. Gynecol Oncol 2007; 104:217-221.
9. Bergeron C, Ferenczy A, Toft DO et al. Immunohistochemical study of progesterone receptors in the human endometrium during the menstrual cycle. Lab Invest 1988; 59: 862-869.
10. Cantley LC, Neel BG.New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase /AKT pathway. Proc Nat Acad Sci USA 1999; 96: 4240-4245.
11. Jeon YT, Kang S, Kang DH, Yoo KY, Park IA, Bang YJ et al. Cyclooxygenase-2 and p53 expression in endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004; 13(9): 1538–42.
12. Macwhinnie N, Monaghan H. The use of P53, PTEN and C-erb-2 to differentiate uterine serous papil-lary carcinoma from endometrioid endometrial carcinoma. Int J Gynecol Cancer 2004; 14: 938-946.
13. Pricop M. Oncologie ginecologică clinică (Clinical Gynecological Oncology), Polirom 2000, 159-160.
Additional Files
Published
Issue
Section
License
COPYRIGHT
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.
COPYRIGHT TRANSFER FORM FOR
REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /
THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI
We, the undersigned authors of the manuscript entitled
_____________________________________________________________________________________
_____________________________________________________________________________________
warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.
- we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
- the manuscript does not break the intellectual property rights of any other person.
- we have read the submitted version of the manuscript and we are fully responsible for the content.
Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):
- ______________________________/_________________________
- ______________________________/_________________________
- ______________________________/_________________________
N.B. All the authors must sign this form
